Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Breakthrough therapy designation (BTD) is an expedited regulatory pathway designed to accelerate the development of novel therapies that potentially provide substantial clinical benefits, particularly ...

In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the ...

Average approval time reduced by 2.5-3.5 years. Breakthrough therapy designation usually increases valuation significantly. Takeover offers typically increase with breakthrough therapy designations.

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...